Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway.
Resistance to tyrosine kinase inhibitors (TKIs), particularly pazopanib, is the primary driver of treatment failure in patients with advanced clear cell renal cell carcinoma (ccRCC). However, the epitranscriptomic mechanisms underlying TKI resistance, especially the regulatory role of N6-methyladenosine (m6A) modificat...